Fluvaxin

Quick links to important sections

Fluvaxin

Selected form

Method of action: Immunostimulants

Treatment option: Influenza, Flu Prevention

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluvaxin

What is Fluvaxin? (Inactivated Influenza Vaccine)

Property Description
Active ingredient Purified Influenza Virus Antigens
Form Suspension for injection
Pharmacological class Vaccine, Immunological Agent
Common use Prophylaxis (Prevention of illness)
Origin Biological product (virus culture-derived)

What Type of Medicine is Fluvaxin?

Fluvaxin is a biological product classified as an Immunological Agent, placing it within the high-level pharmacological class of Vaccines. The medicine is a prophylactic preparation, meaning its primary function is to help prevent disease rather than to treat an existing infection or symptoms. It is consistently manufactured as a Suspension for injection, and standard practice for inactivated influenza vaccines dictates it is typically administered via either Intramuscular or Subcutaneous injection. This format is often positioned for broad annual use across various age groups.


Composition: Inactivated Virus Antigens and Origin

The active components in Fluvaxin are purified Influenza Virus Antigens derived from selected viral strains, which include the key surface structures Hemagglutinin and Neuraminidase. Fluvaxin is characterized as an inactivated vaccine, which means the viral components are entirely non-replicating and cannot cause influenza illness in the recipient. It is a Combination product containing antigens from multiple viral types and is a Biological product suspended in a sterile aqueous solution. The formulation is strain-specific and must be updated annually to target the specific strains predicted to circulate.


What is the General Goal of Fluvaxin?

The primary goal of Fluvaxin is to establish protective immunity against the seasonal influenza virus strains included in the vaccine, supporting essential seasonal preparedness. This is achieved through active immunization, where the body's immune system is trained to recognize the introduced antigens. This process leads to successful antibody production and immunological memory, which primes the body to rapidly neutralize the actual virus if later exposed, helping to reduce the risk of contracting the illness or mitigating its overall severity.

Regulatory References

  1. Immunization - StatPearls - NCBI Bookshelf

What side effects are possible with Fluvaxin?

Fluvaxin: Possible Side Effects and Safety Information

Fluvaxin (Fluvoxamine) has an official safety profile categorized by the frequency and the physiological system affected, as documented in regulatory sources such as the EMA and FDA. These classifications reflect how health authorities organize the medicine's risk characteristics.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Very Common (ge 1/10), typically involve the gastrointestinal and nervous systems, including nausea, vomiting, headache, insomnia, and somnolence. Other frequent reactions, categorized as Common (ge 1/100 to <1/10), include anxiety, dizziness, diarrhea, constipation, and tremor. Rare effects (ge 1/10000 to <1/1000) documented in official labeling include convulsions (seizures) and hepatic enzyme elevation.

Serious Adverse Reactions and Safety Notes

Regulatory documents highlight the potential for serious adverse reactions, notably Serotonin Syndrome, a potentially life-threatening condition associated with increased serotonergic activity. There is also a documented risk of increased suicidal thoughts and behavior (suicidality), particularly in young adults, which is often noted to be highest during the initial phases of therapy or following dose adjustments. Serious physiological reactions such as hyponatremia (low sodium levels) are reported, especially in older adults.

Population and Constraint Information

Specific safety considerations apply to certain groups: an elevated risk of suicidality is documented for pediatric patients (children and adolescents). For older adults, an increased risk of hyponatremia is noted. The medicine is contraindicated in combination with MAOIs (Monoamine Oxidase Inhibitors) and certain other drugs due to the potential for serious safety consequences.

Overdose and Emergency Response

Fluvaxin Overdose and when to seek help

An overdose of Fluvaxin (Fluvoxamine Maleate) is formally documented to present with several distinct clinical manifestations across various systems. These include gastrointestinal effects such as nausea, vomiting, and diarrhea. Central nervous system findings often involve somnolence (drowsiness), dizziness, tremor, and agitation. Cardiovascular effects are also documented, presenting as changes in heart rhythm like tachycardia or bradycardia, as well as hypotension.

Mandated Emergency Actions and Severe Outcomes

Official regulatory guidance strictly requires seeking immediate medical attention or contacting a Poison Control Center for any suspected overdose. This urgent action is necessary due to the risk of severe, life-threatening systemic outcomes. Documented severe manifestations include seizures, coma, and the potentially fatal condition known as Serotonin Syndrome. Furthermore, regulatory documents note that the elderly may have an increased risk of toxicities such as hyponatremia, complicating an overdose presentation.

Official Management and Monitoring

Management protocols officially focus on providing comprehensive symptomatic and supportive treatment, given that no specific antidote is known. This requires maintaining a patent airway and continuous monitoring of cardiac and vital signs. Procedures like gastric lavage or the administration of activated charcoal may be considered, and extended hospital observation is generally required for symptomatic patients.

Therapeutic Uses of Fluvaxin

Fluvaxin (Fluvoxamine) is commonly used in situations involving certain distressing symptoms, and may offer symptomatic relief that helps patients cope more steadily with difficult episodes. It is applied across domains where additional symptomatic support is needed, particularly in conditions characterized by recurrent or episodic manifestations.


Supportive Management of Obsessive-Compulsive Symptoms

This medication plays a role in managing the core features of Obsessive-Compulsive Disorder (OCD), a condition where symptoms cluster into patterns requiring supportive management. It is considered relevant in the context of OCD and Social Anxiety Disorder, where it may assist with addressing pronounced symptoms. Fluvaxin provides support that helps ease the overall symptom burden.

“Fluvaxin provides support that helps ease the overall symptom burden, assisting with reducing the noticeable interference with daily stability.”

Quick Fact: Supportive Symptom Management

  • Target Symptom: Symptoms related to heightened physiological activity and distressing mental manifestations.
  • Clinical Goal: Contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Supportive Assistance with Heightened Anxiety and Distress

Fluvaxin is also relevant in conditions characterized by periods of heightened physiological stress, such as Social Anxiety Disorder (Social Phobia). It is applied in addressing symptom clusters that may become intense or disruptive during acute episodes. The medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability, which may be affected when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Fluvaxin (Fluvoxamine Maleate) eligibility is defined by absolute prohibitions and specific population restrictions documented in regulatory labeling. The medicine is contraindicated and must not be used by patients concurrently taking Monoamine Oxidase Inhibitors (MAOIs), or certain other drugs including tizanidine, pimozide, alosetron, or thioridazine.

Age and Indication Restrictions

Eligibility is limited by age and condition. For pediatric patients, the medicine is approved only for the treatment of Obsessive-Compulsive Disorder (OCD) in those aged 8 to 17 years; safety and effectiveness are not established for children under the age of 8.


Conditional Use and Comorbidities

Special caution is required for certain clinical statuses. Patients with hepatic dysfunction (liver impairment) require careful monitoring and a modified initial use protocol due to decreased clearance. Use is advised to be avoided in cases of unstable epilepsy. Older adult patients may be at an increased risk for hyponatremia.

Use during pregnancy is conditional, and the medicine is secreted into human breast milk, requiring a decision to discontinue nursing or discontinue the drug, as stated in official labeling.

What should I know about interactions with other medicines?

The regulatory profile for Fluvaxin (Fluvoxamine) focuses on the classification of specific contraindicated combinations and its established effects on drug metabolism. Co-administration is formally prohibited with substances such as Tizanidine, Pimozide, Alosetron, and all Monoamine Oxidase Inhibitors (MAOIs). A mandatory two-week washout period is required after stopping an irreversible MAOI before Fluvaxin therapy can be initiated.

Fluvaxin acts as a potent inhibitor of key liver enzymes, primarily CYP1A2 and CYP2C19. This leads to a pharmacokinetic interaction where the clearance is reduced for many co-administered medicines, resulting in significantly increased plasma concentrations (exposure). Medicines affected include Theophylline, Warfarin, and Tricyclic Antidepressants. For Theophylline, the label explicitly notes its dose must be reduced by one-third.

A distinct pharmacodynamic interaction occurs with other serotonergic agents, including certain migraine treatments and the herbal product St. John's Wort, increasing the official risk for Serotonin Syndrome. The risk of bleeding or hemorrhage is documented as being increased when combined with antiplatelet or anticoagulant agents. Population-specific cautions, such as monitoring for heightened interaction risks in patients with hepatic or renal impairment, are noted in the regulatory documentation.

Mechanism of Action

Fluvaxin, chemically Fluvoxamine Maleate, functions mechanistically as a selective serotonin reuptake inhibitor (SSRI) and a sigma-1 receptor (sigma1R) agonist.

In the central nervous system, Fluvaxin selectively targets the neuronal sodium-dependent serotonin transporter (SERT), acting as an inhibitor. This interaction blocks the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft into the presynaptic neuron. The resultant molecular effect is an increased concentration of 5-HT within the synaptic cleft, leading to enhanced and prolonged activation of postsynaptic 5-HT receptors and potentially 5-HT1A autoreceptors. This chronic modification of 5-HT signaling subsequently modulates downstream neural circuitry.

Fluvaxin also exhibits high-affinity agonism at the intracellular sigma1R, a chaperone protein localized primarily at the endoplasmic reticulum. Activation of sigma1R is associated with modulating cellular processes, including regulating neurotrophic factors and influencing the IRE1alpha (inositol-requiring enzyme 1alpha) pathway. This sigma1R activity contributes to the modulation of inflammatory cytokine and gene expression, suggesting an anti-inflammatory cascade at the intracellular level. System-level physiological consequences involve a dual modulation of central monoaminergic neurotransmission and peripheral inflammatory signaling pathways.

Dosage and Administration Information

The administration of Fluvaxin (Fluvoxamine Maleate) is defined by prescribing information concerning the dosage form, schedule, and procedural adjustments.

Administration Method and Form

Fluvaxin is administered exclusively via the oral route. It is supplied as immediate-release tablets in strengths up to 100 mg, and as extended-release capsules in strengths up to 150 mg. The extended-release capsules must be swallowed whole and must not be chewed or crushed to preserve the drug’s intended release profile. The medication may be taken with or without food.

Standardized Dosing and Schedule

For adults, the immediate-release tablet typically starts at 50 mg once daily, often taken at bedtime, while the extended-release capsule starts at 100 mg once daily. The standard regimen targets a total daily dose between 100 mg and 300 mg, which is the maximum recommended daily dose. When the daily dose of the immediate-release tablet exceeds 100 mg, it is administered in two divided doses, with the larger portion typically taken at bedtime.

Procedural Adjustment and Duration

The total daily dose is increased gradually in 50 mg increments, with adjustments occurring every 4 to 7 days for the immediate-release form or at weekly intervals for the extended-release form. Patients with hepatic impairment and older adults should begin with a lower starting dose and undergo a slower titration due to altered drug clearance. When discontinuing the medicine, a gradual dose reduction (tapering) is the standard procedural step.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluvaxin

Evidence for Use in Seasonal Influenza Prophylaxis

Research exploring influenza prevention included two main types of studies: Randomized Controlled Trials (RCTs) and observational studies. RCTs were used to evaluate outcomes in healthy populations, comparing outcomes against a placebo or a different vaccine formulation. Observational studies, frequently used post-licensure, monitored clinical outcomes against the specific virus strains circulating during a given influenza season. Researchers examined outcomes related to laboratory-confirmed influenza and monitored the body's immune response by measuring antibody levels.

Studies monitored measurements of antibody levels across various age groups following administration. Post-licensure observational analyses describe patterns observed in the studies, which can vary annually because the associations explored are related to the match between the vaccine components and the strains that actually circulate. Evidence quality varies across studies based on the season and the study design, with evidence suggests that short-term immune responses were observed in healthy adults.

Evidence for Supportive Symptom Management in OCD and Social Anxiety

The research base for the medicine in the context of Obsessive-Compulsive Disorder (OCD) and Social Anxiety Disorder (SAD) primarily consists of short-term, double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over a defined time interval, typically 6 to 12 weeks. Research was conducted to evaluate whether the medicine was associated with changes in symptoms of conditions characterized by cycles of stability and flare-ups. Outcomes monitored included change in symptom severity using validated scales and measures of daily functioning or activity level.

Trials reported measurements of symptom scale scores in participants with OCD and SAD compared to those who received placebo. Research describes the percentage of participants who reached specific measurement scores after the study period. This evidence contributes to the broader evidence landscape of short-term symptom patterns in these conditions.

Research Gaps and Areas of Uncertainty

A primary limitation in the research is the short duration of many randomized, controlled trials for both contexts. Long-term effects are not fully established, and there is limited information from controlled studies for outcomes over durations greater than 6 months. For supportive symptom management, a high placebo response rate was observed in some studies, which researchers considered in their analyses. Furthermore, evidence is limited for outcomes related to some severe influenza outcomes in specific high-risk groups.

Key Studies & References

  1. Pharmacological Treatment for Obsessive-Compulsive Disorder: A Systematic Review and Network Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Fluvaxin (FAQ)

Q: Does Fluvaxin interact with common vitamins or supplements?

A: Official information indicates that Fluvaxin may interact with certain herbal supplements, such as St. John's Wort and L-tryptophan, which could increase the risk of unwanted serotonergic effects. Official caution is advised regarding the use of all vitamins, supplements, and herbal products.

Q: Is there any food I should avoid when taking Fluvaxin?

A: Official warnings describe avoiding consuming alcohol while using Fluvaxin because of the potential for increased central nervous system side effects like drowsiness. Avoiding grapefruit consumption is also noted in official product information, as it can potentially alter the drug levels in the body.

Q: Are there any long-term effects associated with using Fluvaxin?

A: Official information indicates that the long-term effects of Fluvaxin on the growth, development, and maturation of children and adolescents are not established, as controlled data is limited beyond short-term trials. For adult use, controlled studies providing data on outcomes over long durations are also limited.

Q: Can Fluvaxin be taken with over-the-counter pain relievers?

A: Official product information advises caution when using Fluvaxin alongside certain over-the-counter pain relievers, specifically NSAIDs (like ibuprofen and naproxen) or aspirin. The documented risk of bleeding or hemorrhage is increased with this combination.

Q: Do I need to take Fluvaxin at the exact same time every day?

A: The prescribed schedule often includes taking the medication at bedtime and, for higher total doses, splitting it into two daily portions. Maintaining a consistent time is intended to promote the maintenance of stable drug levels in the body, although the need for the exact same minute each day is not specified in regulatory documentation.

Q: Does taking Fluvaxin require any special monitoring by a doctor?

A: Regulatory documents indicate that patients are to be monitored closely for changes in mood, behavior, or the emergence of suicidal thoughts, particularly when first starting the medication or undergoing dose adjustments. Special monitoring is noted in the labeling for patients with hepatic (liver) impairment.

Q: Are there any known interactions between Fluvaxin and herbal teas?

A: As certain herbal products, such as St. John’s Wort, are known to interact with Fluvaxin, caution should be applied to herbal teas that may contain similar ingredients. Discussing the use of any herbal tea with a healthcare provider is noted in official guidance.

Q: Is Fluvaxin used for chronic conditions or only for short-term problems?

A: Fluvaxin is approved for treating Obsessive-Compulsive Disorder (OCD), which is a chronic (long-term) condition often managed with ongoing therapy. The evidence base for both OCD and Social Anxiety Disorder includes studies designed to evaluate short-term outcomes.

Q: How long does Fluvaxin take to start working?

A: While the drug achieves steady-state levels in the body—meaning a consistent amount—within approximately 5 to 10 days, official information suggests the full therapeutic effect can take several weeks to develop. Patients may experience subtle changes before the full benefit is realized.

Q: If I miss a dose of Fluvaxin, what usually happens?

A: Official product instructions typically describe taking a missed dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the patient is advised to skip the missed dose and continue the regular schedule, avoiding taking a double dose.

Q: What should I do if I think a side effect from Fluvaxin is severe?

A: Official leaflets describe seeking emergency medical attention immediately if a patient experiences symptoms of a severe reaction, such as signs of Serotonin Syndrome or a seizure (convulsion). Serious allergic reactions also require prompt professional care.

Q: Does Fluvaxin affect my ability to drive?

A: Regulatory information notes that Fluvaxin may cause side effects such as drowsiness, dizziness, or impaired judgment, thinking, and motor skills. Regulatory information describes avoiding driving or operating heavy machinery until the individual understands their personal response to the medication.

Q: Is it possible to be allergic to Fluvaxin ingredients?

A: Fluvaxin is contraindicated for use in individuals who have a known allergy to the drug or any of its components. Official information describes that symptoms of a serious allergic reaction require prompt medical attention.

Q: What is the legal classification of Fluvaxin (e.g., controlled substance)?

A: Fluvaxin (Fluvoxamine Maleate) is a medicine that requires a prescription from a licensed healthcare professional. However, according to US regulatory records (DEA), it is not classified as a Controlled Substance.

Q: Is Fluvaxin known to interact with caffeine?

A: Official safety information indicates that Fluvaxin may reduce the clearance of caffeine from the body because it is an inhibitor of the CYP1A2 enzyme. This interaction can lead to increased levels of caffeine in the bloodstream, potentially causing side effects such as increased nervousness or sleeplessness.

Q: How quickly do most people notice an improvement after starting Fluvaxin?

A: Studies suggest that while patients may notice subtle changes within the first 5 to 10 days as the drug reaches consistent levels in the body, the full therapeutic benefit of Fluvaxin typically takes several weeks to become fully apparent.

Q: Are there any restrictions on alcohol consumption while using Fluvaxin?

A: Official warnings describe avoiding the consumption of alcohol while taking Fluvaxin. Combining alcohol with this type of psychotropic medication may lead to additive effects on the central nervous system, which can result in increased symptoms like drowsiness.

Q: Are there any blood tests required before or during treatment with Fluvaxin?

A: Due to the potential risk of hyponatremia (low sodium levels in the blood), especially in older adults, monitoring of sodium levels may be required by a healthcare provider. This monitoring is most likely to occur when beginning the medication or following dose adjustments.

Q: What if I experience a rare or unexpected side effect from Fluvaxin?

A: Official information describes contacting a healthcare provider immediately if any side effect is experienced that is severe, unusual, or worsening. If symptoms appear life-threatening, emergency medical care should be sought.

Q: Are there specific warnings about Fluvaxin for people with heart problems?

A: Official patient information advises that individuals who have a history of a recent heart attack, certain heart diseases, or specific heart rhythm problems (like QT prolongation) should use Fluvaxin with caution. This indicates that these conditions are relevant safety considerations.

How should Fluvaxin be stored and disposed of?

How to Store and Dispose of Fluvoxamine Maleate Tablets

The storage and disposal instructions for Fluvoxamine Maleate Tablets are strictly regulated to maintain product stability and safety.

Storage Requirements

Requirement Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environment Protect from heat, moisture, and direct light. Do not freeze.
Container Keep the medicine in a closed container.
Safety Keep out of the reach of children.

Disposal

Outdated or no longer needed medicine must be disposed of. Individuals should consult a healthcare professional or pharmacist for the proper method to safely discard the unused product, according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluvaxin found in:

A-Z Index: